Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

With Perjeta, The Cost Of HER2 Breast Cancer Therapy Goes Up

Related Content

Genentech’s <em>Perjeta</em> Clears FDA Despite Unresolved Manufacturing Issues

Jun 18 2012

Merck, Lilly Vow To Press On With CETP, Despite Dalcetrapib Disaster

May 07 2012

Pfizer’s <i>Xalkori</i> Joins The Six-Figure Oncology Drug Club

Sep 05 2011

Beyond Herceptin, Roche Readies Breast Cancer Successors, Braces For Biosimilars

Jun 11 2012

Buoyed By T-DM1 EMILIA Data, Roche Leaps To Early Breast Cancer Trial

Jun 04 2012

Related Companies

Roche Holding AG

Genentech, Inc.

Dendreon Corporation

Bristol Myers Squibb Company

Seagen Inc.

Agilent Technologies, Inc.

ImmunoGen, Inc.

Additional Topics

Reimbursement Pricing Strategies Launches BioPharmaceutical

More from Market Access

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window